Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Dose Escalation Safety and Tolerability Study of VAXINIA (CF33-hNIS), Administered Intratumorally or Intravenously as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Metastatic or Advanced Solid Tumors (MAST)

Next Previous
Trial Profile

A Phase I, Dose Escalation Safety and Tolerability Study of VAXINIA (CF33-hNIS), Administered Intratumorally or Intravenously as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Metastatic or Advanced Solid Tumors (MAST)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; VAXinia (Primary) ; VAXinia (Primary)
  • Indications Advanced breast cancer; Biliary cancer; Cholangiocarcinoma; Colorectal cancer; Gastrointestinal cancer; Liver cancer; Malignant melanoma; Malignant thymoma; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Skin cancer; Solid tumours; Triple negative breast cancer; Urogenital cancer
  • Focus Adverse reactions; First in man
  • Acronyms MAST
  • Sponsors Imugene

Most Recent Events

  • 08 Jun 2025 Planned End Date changed from 1 Jan 2025 to 1 Nov 2026.
  • 08 Jun 2025 Planned primary completion date changed from 1 Dec 2024 to 1 Jun 2026.
  • 05 Nov 2024 According to an Imugene media release, company discussed latest update of this trial stating the trial has maintained a complete response (CR) for over two years.The bile tract cancer expansion of the trial recently also cleared its first patient cohort, with no dose-limiting toxicities observed, and enrolment is now open for up to 10 additional patients.The company continues to recruit patients for the bile tract cancer segment of the trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top